Worldwide Market Reports

Conjugate Vaccines Market Growth: Influencing Trends, Latest News with Growth Forecast, Analytical Statistics

Conjugate Vaccines Market Examination and Industry Growth Till 2025 Which is Going to Change Industry Future


Seattle, WA -- (SBWIRE) -- 11/15/2019 -- Conjugate vaccines are a type of vaccines which typically consists of antigens that are coupled chemically to a protein carrier (PC). The conjugation of proteins with the saccharides converts the polysaccharides to T-dependent antigens which generates robust immune response in adults and infants. In other words, conjugate vaccines are the vaccines which couples a strong antigen to a weak antigen to produce a stronger response to the weak antigen by the immune system.

The market is observing a vibrant growth on account of increasing prevalence of infectious diseases coupled with the rise in awareness to prevent these diseases. Increasing initiatives by the government in the healthcare sector and advancements in the vaccine formulations are further expected to drive the growth of the market. Additionally, the rising investments in research and development and growing demand for vaccination is anticipated to fuel the market growth. Enhancement in the use of these vaccines for adults along with the increase in the number of regulatory approvals are anticipated to boost the market growth over the forecast period i.e. 2019-2027.

Get more info about "Global Conjugate Vaccines Market Report" by requesting Sample Copy HERE:

Market Segmentation:

This report segments the market on the basis of type, disease indication, pathogen type, end user, and region. Based on type, the market is bifurcated into monovalent conjugate vaccines and multivalent conjugate vaccines. Based on disease indication, it is classified into pneumococcal, influenza, diphtheria and pertussis (DTP), meningococcal, and others. Based on pathogen type, it is categorized into bacterial conjugate vaccine, viral conjugate vaccine, and combination (viral and bacterial) conjugate vaccine. Based on the end user, the market is segmented into pediatrics and adults. By geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Growth Factors:

Increased revenue from the sale of meningococcal vaccines and pneumococcal vaccines are driving the global conjugate vaccine market due to increasing advancements in the research and development. Increasing prevalence of infectious diseases and rising awareness toward prevention of these disease is anticipated to boost the global conjugate vaccine market during the forecast period. However, long time interval between the introduction of new conjugate vaccines in low-income countries and high-income countries is likely to restrain the global conjugate vaccine market.

Regional Analysis:

On the basis of regional analysis, the global conjugate vaccines market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region.

North America is anticipated to dominate the overall market of conjugate vaccines on the back of high use of vaccines for preventing various types of diseases combined with increase in investment on research and development activities. Europe is expected to be the second largest market on account of rising healthcare expenditure and sufficient funds for research and development in the field of conjugate vaccines. Further, Asia Pacific region is anticipated to witness fastest growth which can be attributed to the high prevalence of communicable diseases coupled with rising immunization initiatives by different government and private organizations.

Key Players:

Novartis AG, Neuron Biotech, Serum Institute of India, Pfizer, Inc., Sanofi Pasteur, Bharat Biotech, Biological E, GlaxoSmithKline, plc., Merck and Company, and CSL Limited.

Want to make an inquiry before purchasing this report and also want a discount? Click HERE: